Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt(®))

Survey of Ophthalmology

Volumn 44, Issue SUPPL. 2, 2000, Pages S147-S153

  Silver, Lewis H ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

Azopt( ); Brinzolamide; Carbonic anhydrase inhibitor; Open angle glaucoma

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; PLACEBO;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ERYTHEMA; EYE IRRITATION; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN ANGLE GLAUCOMA; PAIN; PRIORITY JOURNAL; PRURITUS; RHINITIS; SUSPENSION; TASTE DISORDER; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0034014371     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6257(99)00110-1     Document Type: Article

References (9)

1. Dean T, May J, Chen HH, et al: Brinzolamide (AL-4862) suspension is a new topically active carbonic anhydrase inhibitor in the Dutch-belted rabbit and cynomolgus monkey (abstract). Invest Ophthalmol Vis Sci 38(suppl):S813, 1997
2. Epstein DL, Grant WM: Carbonic anhydrase inhibitor side effects. Arch Ophthalmol 95:1378-82, 1977
3. Kitazawa Y, Azuma I, Iwata K, et al: Dorzolamide, a typical carbonic anhydrase inhibitor: a two-week dose response study in patients with glaucoma or ocular hypertension. J Glaucoma 3: 275-9, 1994
4. Lippa EA, Carlson L-E, Eriksson L-O, et al: Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 110:495-9, 1992
5. Maus TL, Larsson L-I, McLaren JW, Brubaker RF: Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol 115:45-9, 1997
6. Patel SC, Spaeth GL: Compliance in patients prescribed eye drops for glaucoma. Ophthalmic Surg 26:233-6, 1995
7. Pfeiffer N, Hennekes R, Lippa E, et al: A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients. Br J Ophthalmol 74:405-8, 1990
8. Silver L, Brinzolamide Comfort Study Group: The ocular comfort of brinzolamide 1.0% ophthalmic suspension compared to dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol 44(suppl 2):S141-5, 2000
9. Strahlman E, Tipping R, Vogel R, Dorzolamide Dose-Response Study Group: A six-week dose-response study of the ocular hypotensive effect of dorzolamide with a one-year extension. Am J Ophthalmol 122:183-94, 1996